Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
Javier Gállego(Hospital General Universitario de Elche), Rosário Madero(Hospital Universitario La Paz), A Rodríguez Palomo(Hospital Universitario Central de Asturias), Raquel Hernández(Hospital Municipal de Badalona), Carles Pericay(University Hospital Mútua de Terrassa), Monserrat Mangas(Hospital de Galdakao), Alberto Carmona‐Bayonas(Hospital General Universitario Morales Meseguer), Charlyn Gomez(Marqués de Valdecilla University Hospital), Alicia Hurtado(Universidad de Granada), María Luisa Limón(Sorbonne Université), Isabel Echavarría(Hospital General Universitario Gregorio Marañón), Juana María Cano(Complejo Hospitalario de Navarra), Carlos López(Ministerio de Salud Pública), Laura Visa(Hospital Del Mar), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Aitor Azkárate(Hospital Universitario Insular de Gran Canaria), Avinash Ramchandani(Hospital Universitario Insular de Gran Canaria), Elvira Buxó(Hospital Clínic de Barcelona), Teresa García(Hospital General Universitario Morales Meseguer), Felipe Álvarez Manceñido(Complejo Hospitalario de Navarra), Ana Custodio(Hospital Universitario La Paz), Federico Longo(Instituto Cajal), Ismael Macías(Hospital de Galdakao), A. Viúdez(Universidad Pública de Navarra (UPNA)), A. Lacalle(Hospital General Universitario Gregorio Marañón), M. Sánchez(Complejo Hospitalario de Navarra), Ana Fernández Montés(Instituto Cajal), A. Díaz-Serrano(Research Institute Hospital 12 de Octubre)
Cited by 49
Related Papers
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
|Breast Cancer Research|2014|254
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
|New England Journal of Medicine|2024|208
Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial
|JNCI Journal of the National Cancer Institute|2001|179
Treatment of fractures of the distal radius with a remodellable bone cement
|Journal of Bone and Joint Surgery - British Volume|2000|142